Physician profile
Asad Dean
NPI 1760441885
$1,076,854.25
in general payments reported to CMS, 2019-2025
63 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187K · 2020: $84K · 2021: $146K · 2022: $204K · 2023: $244K · 2024: $112K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $279K · Travel and Lodging: $109K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Consulting Fee: $21K · Food and Beverage: $19K · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $278,742.00 |
| Travel and Lodging | $109,398.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,232.50 |
| Consulting Fee | $20,888.00 |
| Food and Beverage | $18,584.54 |
| Education | $351.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $326,303.79 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $201,603.79 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Janssen Biotech, INC. | $186,720.93 | 2019-2025 | Imbruvica, Erleada, Darzalex |
| Aveo Pharmaceuticals, INC. | $103,313.56 | 2021-2025 | Fotivda |
| Verastem, INC. | $85,133.45 | 2019-2020 | |
| Genzyme Corporation | $66,058.83 | 2019-2025 | |
| Seagen INC. | $54,872.25 | 2019-2023 | Tukysa |
| Astellas Pharma US INC | $14,848.59 | 2019-2023 | Padcev |
| Tg Therapeutics, INC. | $12,340.00 | 2021-2022 | |
| Secura Bio, INC. | $9,438.82 | 2020-2022 | |
| Exelixis INC. | $3,495.06 | 2019 | |
| Sanofi Pasteur INC. | $3,466.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $1,018.73 | 2019-2025 | Imbruvica, Tecvayli, Darzalex |
| Abbvie INC. | $999.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $866.16 | 2019-2025 | Calquence, Enhertu |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.